BR0110877A - Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer - Google Patents

Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer

Info

Publication number
BR0110877A
BR0110877A BR0110877-8A BR0110877A BR0110877A BR 0110877 A BR0110877 A BR 0110877A BR 0110877 A BR0110877 A BR 0110877A BR 0110877 A BR0110877 A BR 0110877A
Authority
BR
Brazil
Prior art keywords
cancer
increasing
topoisomerase inhibitor
dosage
preventing
Prior art date
Application number
BR0110877-8A
Other languages
English (en)
Inventor
Jerome B Zeldis
Andrew Zeitlin
Sol Barer
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR0110877A publication Critical patent/BR0110877A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODOS DE TRATAMENTO DE CâNCER PRIMáRIO DE AUMENTO DA DOSAGEM DE UM INIBIDOR DE TOPOISOMERASE, DE REDUçãO OU PREVENçãO DE UM EFEITO ADVERSO ASSOCIADO COM QUIMIOTERAPIA E COM TERAPIA DE RADIAçãO, DE AUMENTO DA EFICáCIA TERAPêUTICA DE UM INIBIDOR DE TOPOISOMERASE, E DE PROTEçãO DE UM PACIENTE CANCEROSO DOS EFEITOS ADVERSOS ASSOCIADOS COM A ADMINISTRAçãO DE UMA DROGA ANTI-CâNCER, COMPOSIçãO FARMACêUTICA, FORMA DE DOSAGEM, E, KIT PARA USO NO TRATAMENTO DE CâNCER". Esta invenção refere-se às composições compreendendo talidomida e outra droga anti-câncer que podem ser usadas no tratamento ou na prevenção do câncer. Drogas anti-câncer preferias são inibidores de topoisomerase. Uma composição particular compreende talidomida ou um sal, clatrato ou solvato farmaceuticamente aceitável da mesma, e irinotecano. A invenção também se refere aos métodos de tratamento ou prevenção do câncer que compreendem a administração de uma talidomida ou outra droga anti-câncer a um paciente necessitando de um tal tratamento ou de uma tal prevenção. A invenção refere-se em adição aos métodos de redução ou de evitação dos efeitos colaterais adversos associados com a administração de quimioterapia ou de terapia de radiação que compreendem a administração de talidomida a um paciente necessitando de tal redução ou evitação.
BR0110877-8A 2000-05-15 2001-05-10 Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer BR0110877A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20414300P 2000-05-15 2000-05-15
PCT/US2001/015327 WO2001087307A2 (en) 2000-05-15 2001-05-10 Compositions and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR0110877A true BR0110877A (pt) 2003-03-11

Family

ID=22756804

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110877-8A BR0110877A (pt) 2000-05-15 2001-05-10 Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer

Country Status (19)

Country Link
US (2) US7435726B2 (pt)
EP (1) EP1307197B1 (pt)
JP (1) JP5409981B2 (pt)
KR (1) KR100790589B1 (pt)
AR (1) AR029084A1 (pt)
AT (1) ATE322266T1 (pt)
AU (2) AU2001261474B2 (pt)
BR (1) BR0110877A (pt)
CA (1) CA2408707C (pt)
DE (1) DE60118571T2 (pt)
DK (1) DK1307197T3 (pt)
ES (1) ES2258084T3 (pt)
HK (1) HK1054502A1 (pt)
MX (1) MXPA02011218A (pt)
NZ (1) NZ522767A (pt)
PT (1) PT1307197E (pt)
TW (1) TWI289449B (pt)
WO (1) WO2001087307A2 (pt)
ZA (1) ZA200209638B (pt)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
ATE374609T1 (de) * 2000-11-30 2007-10-15 Childrens Medical Center Synthese von 4-aminothalidomid enantiomeren
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
US6440738B1 (en) * 2001-02-08 2002-08-27 Isis Pharmaceuticals, Inc. Antisense modulation of casein kinase 2-beta expression
AU2002249103A1 (en) * 2001-03-29 2002-10-15 Topo Target Aps Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors
IL160960A0 (en) * 2001-09-24 2004-08-31 Tosk Inc Reduced toxicity cisplatin formulations and methods for using the same
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
PT2305255E (pt) * 2001-12-03 2012-09-04 Bayer Healthcare Llc Compostos de arilureia em combinação com outros agentes citostáticos ou citotóxicos para tratamento de cancros humanos
WO2003051382A1 (fr) * 2001-12-14 2003-06-26 Sundory Co., Ltd. Procédé d'induction d'apoptose et compositions pour cette dernière
US20050171036A1 (en) * 2002-03-26 2005-08-04 Banyu Pharmaceutical Co., Ltd. Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination
CN1705439A (zh) * 2002-04-12 2005-12-07 细胞基因公司 干细胞和祖细胞分化的调节、鉴定及其应用
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
EP1496880A4 (en) * 2002-04-24 2007-12-12 Res Dev Foundation SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-kB INHIBITORS AND ANTINEOPLASTIC AGENTS
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
CN1697655B (zh) * 2002-05-17 2013-09-18 细胞基因公司 使用免疫调节性化合物用于治疗和控制癌症和其它疾病的方法及组合物
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
NZ536908A (en) * 2002-05-17 2008-09-26 Celgene Corp Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
CA2489947A1 (en) * 2002-06-24 2003-12-31 Research Development Foundation Treatment of human multiple myeloma by curcumin
US20040034099A1 (en) * 2002-06-27 2004-02-19 Ramsey Beverly J. Pharmaceutical composition
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP1551385A4 (en) * 2002-10-15 2008-10-22 Celgene Corp SELECTIVE CYTOKINE INHIBITOR DRUGS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
MXPA05004780A (es) * 2002-11-06 2005-10-05 Celgene Corp Metodos y composiciones que usan farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de canceres y otros padecimientos.
NZ540384A (en) * 2002-11-06 2008-06-30 Celgene Corp Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
WO2004087713A1 (en) * 2003-03-31 2004-10-14 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
CL2004001004A1 (es) * 2003-05-19 2005-03-18 Upjohn Co Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
WO2004113502A2 (en) * 2003-06-20 2004-12-29 Avalon Pharmaceuticals, Inc. Identification of therapeutic agents using genetic fingerprinting
US7264819B2 (en) * 2003-06-23 2007-09-04 Anticancer, Inc. Lyase treatment for P. carinii
US20050049299A1 (en) * 2003-08-26 2005-03-03 Aggarwal Bharat B. Selective inhibitors of stat-3 activation and uses thereof
WO2006046934A2 (en) 2003-08-26 2006-05-04 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
EA200600921A1 (ru) * 2003-11-06 2006-10-27 Селджин Корпорейшн Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
NZ548049A (en) * 2003-12-02 2009-01-31 Celgene Corp Methods and compositions for the treatment and management of hemoglobinopathy and anemia
ATE427943T1 (de) * 2003-12-12 2009-04-15 Quiral Quimica Do Brasil Verfahren zur herstellung von wasserfreien und hydratisierten pharmazeutischen wirkstoffen (apis); aus diesen hergestellte stabile pharmazeutische zusammensetzungen und anwendungen fur diese zusammensetzungen
EP1722777A2 (en) * 2004-02-20 2006-11-22 Arqule, Inc. Use of beta-lapachone for the treatment of pancreatic cancer
EP1729760A2 (en) * 2004-02-20 2006-12-13 Arqule, Inc. Use of beta-lapachone for the treatment of lung cancer
CA2555941A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treatment of colon cancer
JP2007523956A (ja) * 2004-02-25 2007-08-23 ダナ−ファーバー キャンサー インスティテュート インク． 腫瘍細胞増殖を阻害するための方法
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
LT2574341T (lt) 2004-03-29 2017-09-11 University Of South Florida Navikų ir vėžio efektyvus gydymas triciribino fosfatu
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100173864A1 (en) * 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
JP2007532642A (ja) * 2004-04-14 2007-11-15 セルジーン・コーポレーション 脊髄形成異常症候群の治療及び管理のための選択的サイトカイン阻害薬の使用法、及びそれを含む組成物
BRPI0418742A (pt) * 2004-04-14 2007-09-11 Celgene Corp métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
RU2408387C2 (ru) * 2004-04-27 2011-01-10 Веллстат Байолоджикс Корпорейшн Лечение злокачественного новообразования с применением вирусов и камптотецинов
CN1984652A (zh) * 2004-05-05 2007-06-20 细胞基因公司 使用选择性细胞因子抑制药治疗和控制骨髓增生性疾病的方法和组合物
CN1984651A (zh) * 2004-05-05 2007-06-20 细胞基因公司 使用选择性细胞因子抑制药治疗和控制癌症和其它疾病的方法和组合物
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
NZ564954A (en) * 2005-06-14 2011-02-25 Protox Therapeutics Inc Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
CA2640598A1 (en) * 2006-02-03 2007-08-09 Noboru Yamazaki Liposome preparation
US20100021519A1 (en) * 2006-04-27 2010-01-28 Narmada Shenoy Compositions and Methods for Treating or Preventing Diseases of Body Passageways
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP2014651A1 (en) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
US7893045B2 (en) 2007-08-07 2011-02-22 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
US20100311683A1 (en) * 2007-11-01 2010-12-09 Beach C L Cytidine analogs for treatment of myelodysplastic syndromes
SI2219451T1 (sl) * 2007-11-21 2015-02-27 Oxigene, Inc. Postopek za zdravljenje hematopoetskih neoplazem
US20090137631A1 (en) * 2007-11-22 2009-05-28 National Yang-Ming University Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
CA2751892A1 (en) 2009-01-15 2010-07-22 Rutgers, The State University Of New Jersey Benzo [c] phenanthridines as antimicrobial agents
WO2010127307A1 (en) 2009-04-30 2010-11-04 Rutgers, The State University Of New Jersey Antimicrobial agents
CA2810162A1 (en) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
US9102617B2 (en) 2010-06-25 2015-08-11 Rutgers, The State University Of New Jersey Antimicrobial agents
AU2011352036A1 (en) 2010-12-31 2013-07-18 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
KR101369936B1 (ko) * 2011-12-28 2014-03-06 연세대학교 산학협력단 탈리도마이드를 포함하는 루프스 신염 치료용 약학 조성물
US9822108B2 (en) 2012-01-13 2017-11-21 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2013142712A1 (en) 2012-03-21 2013-09-26 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2014180882A2 (en) * 2013-05-07 2014-11-13 Universitat De Barcelona Treatment of brain metastasis from cancer
US20170080093A1 (en) * 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
RS64038B1 (sr) 2014-08-22 2023-04-28 Celgene Corp Postupci za lečenje multiplog mijeloma imunomodulatornim jedinjenjima u kombinaciji sa antitelima
SI3313818T1 (sl) 2015-06-26 2024-03-29 Celgene Corporation Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
US10513528B2 (en) 2016-02-25 2019-12-24 Taxis Pharmaceuticals, Inc. Synthetic processes and intermediates
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
KR101851470B1 (ko) 2016-12-19 2018-06-11 한림대학교 산학협력단 퀘세틴이 함유된 유방암 예방 및 치료를 위한 약제학적 조성물
CN110891566B (zh) 2017-03-30 2023-12-19 塔克西斯医药股份有限公司 合成方法和合成中间体
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5422344A (en) * 1990-05-08 1995-06-06 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Method of treating retroviral infections in mammals
WO1992014455A1 (en) 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5643915A (en) 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5654312A (en) 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
GB9523493D0 (en) * 1995-11-16 1996-01-17 British Biotech Pharm Preparation of allyl succinate derivatives and starting materials therefore

Also Published As

Publication number Publication date
HK1054502A1 (en) 2003-12-05
JP2003533484A (ja) 2003-11-11
AR029084A1 (es) 2003-06-04
DE60118571D1 (de) 2006-05-18
KR20030025922A (ko) 2003-03-29
CA2408707A1 (en) 2001-11-22
US7435726B2 (en) 2008-10-14
US20020035090A1 (en) 2002-03-21
AU2001261474B2 (en) 2006-03-09
AU6147401A (en) 2001-11-26
US20050148524A1 (en) 2005-07-07
TWI289449B (en) 2007-11-11
WO2001087307A2 (en) 2001-11-22
DE60118571T2 (de) 2007-02-01
WO2001087307A3 (en) 2002-07-25
ATE322266T1 (de) 2006-04-15
PT1307197E (pt) 2006-08-31
ZA200209638B (en) 2003-11-27
KR100790589B1 (ko) 2008-01-02
JP5409981B2 (ja) 2014-02-05
DK1307197T3 (da) 2006-07-03
CA2408707C (en) 2010-04-13
EP1307197B1 (en) 2006-04-05
EP1307197A2 (en) 2003-05-07
ES2258084T3 (es) 2006-08-16
NZ522767A (en) 2004-07-30
MXPA02011218A (es) 2004-08-19

Similar Documents

Publication Publication Date Title
BR0110877A (pt) Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
BRPI0406667A (pt) Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
BR0207024A (pt) Medicamento com ação inicial rápida para o tratamento de disfunção sexual
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
CR8352A (es) Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos
RS114004A (en) Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
GEP20053595B (en) Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment
BRPI0416260A (pt) método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica
CA2442168A1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
AU2002305952B2 (en) Pharmaceutical combinations
BRPI0415649A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
WO2007112274A3 (en) Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
BRPI0511800A (pt) tratamento com irinotecano (cpt-11) e um inibidor de egfr
AP1780A (en) Use of cox-2 inhibitors for preventing immunodeficiency.
AU2002305952A1 (en) Pharmaceutical combinations
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
KR20020069201A (ko) 약학 조합제제
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
BR0214135A (pt) Produto farmacêutico, dose farmacêutica, usos de um anti-estrogênio e de um inibidor da aromatase e 4'-ciano-alfa', alfa, alfa'-trifluoro-3-(4-fluorofenilsulfonil)-2-hidróxi-2- metilpropiono-m-toluidida ou um sal ou solvato farmaceuticamente aceitáveis destes, e, método para tratar de câncer da próstata e/ou reduzir o risco de câncer da próstata em um paciente
BR112023002295A2 (pt) Terapia de combinação
MXPA06007510A (es) Composiciones de farmaco y formas de dosis novedosas de topiramato.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time